ClinicalTrials.gov
public full text
Public Domain
TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Shortening Treatment by Advancing Novel Drugs#1153608
- Effects of pyrazinamide and/or ethambutol resistance on Tuberculosis treatment outcome by whole genome sequencing, South Africa 2020 – 2022#447668
- TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment#839951
- Development of novel bioanalytical assays and an objective adherence measure of key second-line tuberculosis drugs#666629
- Evaluating Newly Approved Drugs for Multidrug-resistant TB#980001
Record · ID 855887
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive